↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Oberg B.) "

Sökning: WFRF:(Oberg B.)

Resultat 1-10 av 118

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Pedersen, TR, et al. (författare) Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study 1996 Ingår i: Circulation. - 0009-7322. ; 93:10, s. 1796-1802 Tidskriftsartikel (refereegranskat)
2.	Andersson, H.O., et al. (författare) Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors 2003 Ingår i: European Journal of Biochemistry. - : Wiley. - 0014-2956 .- 1432-1033. ; 270:8, s. 1746-1758 Tidskriftsartikel (refereegranskat)abstract HIV-1 protease is an important target for treatment of AIDS, and efficient drugs have been developed. However, the resistance and negative side effects of the current drugs has necessitated the development of new compounds with different binding patterns. In this study, nine C-terminally duplicated HIV-1 protease inhibitors were cocrystallised with the enzyme, the crystal structures analysed at 1.8-2.3 Å resolution, and the inhibitory activity of the compounds characterized in order to evaluate the effects of the individual modifications. These compounds comprise two central hydroxy groups that mimic the geminal hydroxy groups of a cleavage-reaction intermediate. One of the hydroxy groups is located between the d-oxygen atoms of the two catalytic aspartic acid residues, and the other in the gauche position relative to the first. The asymmetric binding of the two central inhibitory hydroxyls induced a small deviation from exact C2 symmetry in the whole enzyme-inhibitor complex. The study shows that the protease molecule could accommodate its structure to different sizes of the P2/P2' groups. The structural alterations were, however, relatively conservative and limited. The binding capacity of the S3/S3' sites was exploited by elongation of the compounds with groups in the P3/P3' positions or by extension of the P1/P1' groups. Furthermore, water molecules were shown to be important binding links between the protease and the inhibitors. This study produced a number of inhibitors with Ki values in the 100 picomolar range.
3.	Bottiger, D, et al. (författare) Inhibition of SIV and HIV-2 replication in cynomolgus monkeys by (-)9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) 1996 Ingår i: ANTIVIRAL CHEMISTRY & CHEMOTHERAPY. - 0956-3202. ; 7:1, s. 21-26 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
4.	Nordenfelt, E, et al. (författare) No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production 1982 Ingår i: Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology. - 0108-0180. ; 90:6, s. 449-451 Tidskriftsartikel (refereegranskat)abstract The efficient in vitro inhibition of hepatitis B virus DNA polymerase by trisodium phosphonoformate (PFA, INN: foscarnet sodium) and its low toxicity suggested that PFA could be used as a therapeutic agent for hepatitis B infection. PFA was also found to inhibit woodchuck hepatitis virus (WHV) DNA polymerase in vitro. As a model to test PFA's eventual effect, chronically WHV infected woodchucks were treated with PFA. The animals were treated twice daily in a dosage which gave a minimum serum level of PFA corresponding to an in vitro inhibiting effect on WHV DNA polymerase of about 40%. The concentration in liver tissue was found to be 15% below serum level. The amount of WHV particles in serum was followed by DNA polymerase assay. No effect on WHV production could be seen during 2 weeks' treatment. No change of the in vitro sensitivity to PFA of the WHV DNA polymerase was seen. These results indicate that the WHV associated DNA polymerase has no role in the production of viral particles.
5.	Zuber, B, et al. (författare) An in vivo model for HIV resistance development 2001 Ingår i: AIDS research and human retroviruses. - : Mary Ann Liebert Inc. - 0889-2229 .- 1931-8405. ; 17:7, s. 631-635 Tidskriftsartikel (refereegranskat)
6.	Berglund, A, et al. (författare) Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial 2002 Ingår i: Medical oncology (Northwood, London, England). - 1357-0560. ; 19, s. 151- Tidskriftsartikel (refereegranskat)
7.	Bergstrom, M, et al. (författare) In vivo demonstration of enzyme activity in endocrine pancreaticPA to carbon-11-dopamine. 1996 Ingår i: J Nucl Med. ; 37, s. 32- Tidskriftsartikel (refereegranskat)
8.	Bergstrom, M, et al. (författare) Pet for visualization of C-11-L-DOPA uptake and decarboxylation in endocrine pancreas cancer 1995 Ingår i: EUROPEAN JOURNAL OF CANCER. - 0959-8049. ; 31A, s. 548-548 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
9.	BJORKHOLM, M, et al. (författare) Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison 1995 Ingår i: European journal of haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 55:1, s. 19-23 Tidskriftsartikel (refereegranskat)
10.	Bjorkholm, M, et al. (författare) Mitoxantrone, etopside and ara-C vs doxorubicin-DNA, ara-C, thioguanine, voncristine and prednisolone in the treatment of patients with acute myelocytic leukemia. A randomized comparison. 1995 Ingår i: Eur J Haematol. ; 55, s. 19- Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 118

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (92); konferensbidrag (22); forskningsöversikt (2); bokkapitel (2)

Typ av innehåll: refereegranskat (82); övrigt vetenskapligt/konstnärligt (35); populärvet., debatt m.m. (1)

Författare/redaktör: Oberg, K (38); OBERG, B (32); Eriksson, B (26); Zhang, H. (11); VRANG, L (11); JOHANSSON, NG (9); visa fler...; UNGE, T (9); Larsson, H (6); Rickert, M (6); Tiensuu Janson, E (6); Gahrton, G (6); Oberg, AS (6); Bjorkholm, M (6); LIND, P (6); NOREEN, R (6); SAHLBERG, C (6); Lichtenstein, P. (6); Almqvist, C (5); Larsson, T (5); Larsson, C (5); HOGBERG, M (5); Weber, G. (4); Stridsberg, M (4); Wang, S (4); Schiöth, Helgi B. (4); Arver, Stefan (4); Jokinen, Jussi (4); Ljungman, P (4); Oberg, Kjell (4); Chatzittofis, Andrea ... (4); Paul, C (4); Turesson, I (3); Tidefelt, U (3); Lonnqvist, B (3); AHGREN, C (3); CANTRELL, AS (3); JASKUNAS, SR (3); JORDAN, CL (3); KINNICK, MD (3); MORIN, JM (3); MUESING, MA (3); Bjurling, P (3); Ahlstrom, H (3); Langstrom, B (3); Harmenberg, J (3); UTTER, G (3); Samuelsson, B (3); LILIEMARK, J (3); GRUBER, A (3); Åkerström, Göran (3); visa färre...

Lärosäte: Karolinska Institutet (62); Uppsala universitet (50); Umeå universitet (6); Lunds universitet (6); Kungliga Tekniska Högskolan (3); Linköpings universitet (3); visa fler...; Göteborgs universitet (2); Örebro universitet (1); Chalmers tekniska högskola (1); visa färre...

Språk: Engelska (117); Svenska (1)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (14); Naturvetenskap (4); Teknik (3); Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy